Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies targeting solid tumor cancers. Its core technology cen... Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies targeting solid tumor cancers. Its core technology centers on tumor infiltrating lymphocyte (TIL) therapy, which leverages a patient's own immune cells to attack a wide range of cancer types, including metastatic melanoma, cervical cancer, non-small cell lung cancer, and several others. The company’s lead marketed product, Amtagvi, is a tumor-derived autologous T cell immunotherapy for adult patients with unresectable or metastatic melanoma, while its pipeline features therapies under investigation for additional tumor types and blood cancers. Iovance is recognized for its proprietary cell therapy platforms and collaborations with leading research institutions. Its approach—harnessing and reinvigorating the body's own T cells—places it at the forefront of personalized immunotherapies in oncology, aiming to redefine treatment strategies for difficult-to-treat cancers and advance the field of immune-based cancer therapeutics.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Iovance Biotherapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Iovance Biotherapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Iovance Biotherapeutics's data?

Create a free Tracenable account to signal interest in having our team review data for Iovance Biotherapeutics.

Legal Center Contact Us